Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2140486 | Lung Cancer | 2016 | 7 Pages |
Abstract
Unsurprisingly, untreated patients had poorer prognostic features and worse OS. However, it is concerning that, despite being seen in an active academic center, nearly half of all referred patients with advanced NSCLC received no anti-cancer treatment. Current research primarily seeks to improve outcomes in treated patients with good PS. This review suggests that this is an inappropriate allocation of research effort. Our research should be more equitably split between good and poor performance patient groups if we are to improve the survival of all patients with advanced NSCLC. Potential strategies include more rapid diagnosis prior to functional decline, and the development of therapies effective and tolerated in a sicker population.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stephanie Y. Brule, Khalid Al-Baimani, Hannah Jonker, Tinghua Zhang, Garth Nicholas, Glenwood Goss, Scott A. Laurie, Paul Wheatley-Price,